There was no significant correlation between NRP-1 RNA level and age, platelet count, LDH, BM blast %, CD33, CD13
, CD14, CD61, myeloperoxidase, CD2, CD7, CD34, HLA-DR, CD10, or survival time.
The catalytic domain of CD13
faces the exterior of the plasma membrane and is anchored by a transmembrane-spanning domain, which is composed of N-terminal residues 9-32 (2).
Mast cells also variably express CD11b, CD13
, CD18, CD22, CD35, CD40, and CD61.
Antigen Mo, M1, M2 M3 M4, M5 M6 M7 CD13
and 33 + (a) + + + [+ or -] HLA-DR + - + [+ or -] [+ or -] CD64 [+ or -] [+ or -] + - - CD14 - - [+ or -] - - CD36 [+ or -] - + + + CD71 [+ or -] [+ or -] [+ or -] + [+ or -] Glycophorin A - - - [+ or -] - CD41 and 61 - - - - + (a) +, positive; -, negative; [+ or -], not definitive.
Acute myelogenous leukemia is easier to distinguish from IVLBCL, because the immunophenotype is less similar (ie, myeloid-associated antigens such as CD13
and CD33 are noted, instead of the B-cell antigens of IVLBCL).
Accordingly, reactivity for the lymphoid markers Tdt, CD2, CD7, and CD19 was demonstrated in MPO+ myeloid leukemic cells (68-73, 75-80), whereas positivity for the myeloid antigens CD13
, CD33, and CD15 can be found in a variable proportion of ALL cases (50, 54, 74).
Flow cytometric analysis showed that these blasts were positive for myeloperoxidase, CD15, CD33, CD13
, CD14, and CD4.
The blast cells in t(8; 21) subtype show high-intensity expression of CD34, HLA-DR (human leukocyte antigenDR), myeloperoxidase, CD13
, with weak CD33 expression.
molecule has been reported as identical to AlaAP (24), and immunocytochemical findings have shown that it is present on healthy breast epithelium and in breast carcinomas (25).
High myeloid expression of CD13
, CD33, and CD15 in 75% of lymphoblasts in Ph(-) ALL has been observed.
By flow cytometry, common granulocytic/neutrophilic lineage-associated antigens are expressed including CD13
, CD15, CD33, and myeloperoxidase.
The results of a previous study involving an inhibition assay with specific monoclonal anti-CD13
antibodies [3, 5] demonstrated that aminopeptidase activity in sera from healthy individuals and patients with hepatobiliary disorders is predominantly attributable to CD13